Sponsors, researchers and Institutional Review Boards (IRBs) are often wary about payments in research participation, citing concerns about coercion and undue influence, whether real or perceived, and have avoided payments that are “too high.” New research on how people make decisions about research participation, and new approaches to this question, bring a new perspective; are payments to participants actually too low? This paper explores this question, and whether we should, in fact, worry much less about restricting compensation for research participants.Enter content here
Most Recent Flipbooks
More Than Good Intentions: Diversity, Equity & Inclusion Requires a Program-Level, Strategic Framework
The Top 5 Benefits of Outsourcing Expert Committee Management to an Independent Provider
The Challenge of Overreporting: A Fresh Perspective from the FDA
In a recent webinar, Steven Beales, Senior VP, Scientific and Regulatory at WCG, facilitated a conversation with FDA leaders, discussing overreporting SUSARs and the impact on patient safety.
Whitepaper - The Power of More Re-Imagining the Traditional Business Model for Oncology Clinical Research
